• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

回顾性临床访谈量表修订版(rCIS-R)评估初级保健患者抑郁症复发的可靠性。

Reliability of the retrospective Clinical Interview Schedule Revised (rCIS-R) to assess relapse in depression in primary care patients.

机构信息

Division of Psychiatry, University College London, London, United Kingdom.

Research Dept. of Primary Care and Population Health, University College London, London, United Kingdom.

出版信息

PLoS One. 2023 Mar 16;18(3):e0280997. doi: 10.1371/journal.pone.0280997. eCollection 2023.

DOI:10.1371/journal.pone.0280997
PMID:36928675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10019660/
Abstract

OBJECTIVES

We are not aware of a simple and short structured measure that retrospectively assesses time to relapse for depression. We developed the retrospective Clinical Interview Schedule Revised (rCIS-R) to assess depression relapse in the previous 12 weeks, for use in a clinical trial of maintenance antidepressant treatment. We assessed test-retest reliability and construct validity in relation to a Global Rating Question (GRQ) about worsening mood, participants stopping their study medication and Patient Health Questionnaire (PHQ-9) scores.

METHODS

In our study 444 participants provided data for rCIS-R, GRQ and PHQ-9 and 396 participants completed rCIS-R on two occasions about 30 minutes apart. The reliability study was nested within a randomised controlled trial (ANTLER).

RESULTS

We found substantial test-retest agreement for the rCIS-R definition of relapse (kappa 0.84 (95%CI 0.71 to 0.97)), for individual sections and timing of relapse (Intraclass Correlation Coefficient 0.94 (95%CI 0.92 to 0.95)). Comparison of relapse with GRQ, stopping study medication and PHQ-9 supported the construct validity of the rCIS-R.

CONCLUSIONS

The rCIS-R provides a reliable way of assessing relapse of depression over the previous 12 weeks. Its brevity, self-report format, simplicity of scoring and absence of training requirement makes it attractive to use in randomised controlled trials.

摘要

目的

我们不清楚是否有一种简单而简短的结构化措施可以回顾性评估抑郁症的复发时间。我们开发了回顾性临床访谈量表修订版(rCIS-R),以评估过去 12 周内的抑郁症复发情况,用于维持抗抑郁治疗的临床试验。我们评估了与关于情绪恶化的总体评定问题(GRQ)、参与者停止研究药物和患者健康问卷(PHQ-9)评分相关的重测信度和结构效度。

方法

在我们的研究中,444 名参与者提供了 rCIS-R、GRQ 和 PHQ-9 的数据,396 名参与者在大约 30 分钟的间隔内两次完成了 rCIS-R。可靠性研究嵌套在一项随机对照试验(ANTLER)中。

结果

我们发现 rCIS-R 对复发的定义(kappa 0.84(95%CI 0.71 至 0.97))具有实质性的重测一致性,对于各个部分和复发时间(组内相关系数 0.94(95%CI 0.92 至 0.95))也是如此。与 GRQ、停止研究药物和 PHQ-9 的比较支持了 rCIS-R 的结构效度。

结论

rCIS-R 提供了一种可靠的方法来评估过去 12 周内抑郁症的复发情况。它的简短、自我报告格式、评分的简单性以及无需培训要求使其在随机对照试验中具有吸引力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f99/10019660/a9778c500524/pone.0280997.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f99/10019660/598adba44e78/pone.0280997.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f99/10019660/a9778c500524/pone.0280997.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f99/10019660/598adba44e78/pone.0280997.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9f99/10019660/a9778c500524/pone.0280997.g002.jpg

相似文献

1
Reliability of the retrospective Clinical Interview Schedule Revised (rCIS-R) to assess relapse in depression in primary care patients.回顾性临床访谈量表修订版(rCIS-R)评估初级保健患者抑郁症复发的可靠性。
PLoS One. 2023 Mar 16;18(3):e0280997. doi: 10.1371/journal.pone.0280997. eCollection 2023.
2
Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.在初级保健中使用抗抑郁药物预防抑郁症复发:ANTLER RCT。
Health Technol Assess. 2021 Nov;25(69):1-62. doi: 10.3310/hta25690.
3
A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial.一项评估西酞普兰、舍曲林、氟西汀和米氮平在长期服用维持性抗抑郁药的初级保健患者中预防复发的随机对照试验(ANTLER:预防抑郁症复发的抗抑郁药):一项随机对照试验的研究方案。
Trials. 2019 Jun 3;20(1):319. doi: 10.1186/s13063-019-3390-8.
4
Is Treatment Working? Detecting Real Change in the Treatment of Child and Adolescent Depression.治疗是否有效?在儿童和青少年抑郁症治疗中检测真正的变化。
J Am Acad Child Adolesc Psychiatry. 2019 Dec;58(12):1157-1164. doi: 10.1016/j.jaac.2019.02.011. Epub 2019 Feb 27.
5
The reliability and validity of PHQ-9 in patients with major depressive disorder in psychiatric hospital.PHQ-9 在精神病院重度抑郁症患者中的信度和效度。
BMC Psychiatry. 2020 Sep 29;20(1):474. doi: 10.1186/s12888-020-02885-6.
6
Monitoring depression treatment outcomes with the patient health questionnaire-9.使用患者健康问卷-9监测抑郁症治疗结果。
Med Care. 2004 Dec;42(12):1194-201. doi: 10.1097/00005650-200412000-00006.
7
Assessing depression in primary care with the PHQ-9: can it be carried out over the telephone?使用患者健康问卷-9(PHQ-9)在基层医疗中评估抑郁症:能否通过电话进行?
J Gen Intern Med. 2005 Aug;20(8):738-42. doi: 10.1111/j.1525-1497.2005.0144.x.
8
Screening for depression with the Patient Health Questionnaire-2 (PHQ-2) among the general population in Hong Kong.在香港的普通人群中,使用患者健康问卷-2(PHQ-2)进行抑郁筛查。
J Affect Disord. 2011 Nov;134(1-3):444-7. doi: 10.1016/j.jad.2011.05.007. Epub 2011 Jun 12.
9
Preliminary validity and test-retest reliability of two depression questionnaires compared with a diagnostic interview in 99 patients with chronic pain seeking specialist pain treatment.两种抑郁问卷与诊断访谈在 99 名寻求专科疼痛治疗的慢性疼痛患者中的初步有效性和重测信度比较。
Scand J Pain. 2020 Oct 25;20(4):717-726. doi: 10.1515/sjpain-2020-0042.
10
Text Messaging as a Screening Tool for Depression and Related Conditions in Underserved, Predominantly Minority Safety Net Primary Care Patients: Validity Study.短信作为服务欠缺、主要为少数族裔的安全网初级保健患者中抑郁症及相关病症筛查工具的效度研究。
J Med Internet Res. 2020 Mar 26;22(3):e17282. doi: 10.2196/17282.

本文引用的文献

1
Antidepressant medication to prevent depression relapse in primary care: the ANTLER RCT.在初级保健中使用抗抑郁药物预防抑郁症复发:ANTLER RCT。
Health Technol Assess. 2021 Nov;25(69):1-62. doi: 10.3310/hta25690.
2
Maintenance or Discontinuation of Antidepressants in Primary Care.在初级保健中维持或停止使用抗抑郁药。
N Engl J Med. 2021 Sep 30;385(14):1257-1267. doi: 10.1056/NEJMoa2106356.
3
A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial.
一项评估西酞普兰、舍曲林、氟西汀和米氮平在长期服用维持性抗抑郁药的初级保健患者中预防复发的随机对照试验(ANTLER:预防抑郁症复发的抗抑郁药):一项随机对照试验的研究方案。
Trials. 2019 Jun 3;20(1):319. doi: 10.1186/s13063-019-3390-8.
4
Depression: Screening and Diagnosis.抑郁症:筛查与诊断。
Am Fam Physician. 2018 Oct 15;98(8):508-515.
5
Inter-rater reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II).DSM-IV 轴 I 障碍(SCID I)和轴 II 障碍(SCID II)的结构性临床访谈的评定者间信度。
Clin Psychol Psychother. 2011 Jan-Feb;18(1):75-9. doi: 10.1002/cpp.693.
6
Management of depression in UK general practice in relation to scores on depression severity questionnaires: analysis of medical record data.英国普通医疗中抑郁症管理与抑郁症严重程度问卷得分的关系:病历数据分析
BMJ. 2009 Mar 19;338:b750. doi: 10.1136/bmj.b750.
7
Risk for recurrence in depression.抑郁症复发的风险。
Clin Psychol Rev. 2007 Dec;27(8):959-85. doi: 10.1016/j.cpr.2007.02.005. Epub 2007 Mar 3.
8
Report by the ACNP Task Force on response and remission in major depressive disorder.美国神经精神药理学院(ACNP)关于重度抑郁症反应与缓解的特别工作组报告。
Neuropsychopharmacology. 2006 Sep;31(9):1841-53. doi: 10.1038/sj.npp.1301131. Epub 2006 Jun 21.
9
A rating scale for depression.一种抑郁症评定量表。
J Neurol Neurosurg Psychiatry. 1960 Feb;23(1):56-62. doi: 10.1136/jnnp.23.1.56.
10
An inventory for measuring depression.一份用于测量抑郁的量表。
Arch Gen Psychiatry. 1961 Jun;4:561-71. doi: 10.1001/archpsyc.1961.01710120031004.